TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07356973: Open-label Phase 2 Safety and Efficacy Trial of Irinotecan-ChemoSeed Administered Directly Into the Resection Margin in Patients With Surgically Resectable Glioblastoma

Sponsor: CRISM Therapeutics LTD · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 147 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07356973 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07356973 Rescue Dossier →